Fosun Invests in Miacom; Will Market and Make its Diagnostic Tests

Fosun Pharma acquired a 37% stake in miacom diagnostics GmbH of Germany in early July for an undisclosed sum. Two weeks later, Fosun Diagnostics announced it would market miacom’s molecular beacon-based diagnostic assays in China and Asia. The proprietary multiplex assays are used to detect sepsis- and pneumonia-related pathogens. In addition, Fosun will build an FDA-compliant production facility to manufacture the assays in China for domestic and export markets. More details.... Stock Symbol: (SHA: 600196; HK: 2196) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.